Biomedica Immunoassays

300 €

Contact us!

Borrelia IgM ELISA

Recombinant antigens for better reproducibility. - CE marked - for IVD use in EU.


Assay characteristics:

Cat.No.: BI-21042
Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
Sample type:Serum, plasma, CSF
Controls:3 vials (negative, cut-off, positive)
Sample size:100 µl (diluted sample) / well
Incubation time:1 h / 30 min / 15 min

Serum: 100%

Serum: 96%

Intra-assay (n=12) ≤ 7%, Inter-assay (n=17) ≤ 8%

Principle of the assay:

Manual ELISAs - easily adaptable for automation! 

Back to top


Click link for:

BI-21042 Borrelia IgM ELISA IFU

Back to top


Lyme borreliosis is a bacterial infection caused by the spirochaete Borrelia burgdorferi sensu stricto, afzellii, or garinii, and is characterised by a variety of clinical symptoms. It can be divided into 3 stages:

Stage 1, early dermatitis, Clinical: erythema migrans.

Stage 2, early disseminated infection, Clinical: lymphocytic meningoradiculitis (Bannwarth's syndrome), neuroborreliosis.

Stage 3, late disseminated infection, Clinical: chronic progressive encephalomyelitis, acrodermatitis chronica atrophicans (ACA), chronic arthritis.

To improve the diagnostic specifity, the Biomedica microwell strips are coated with the following recombinant antigens:
· p21 = OspC (outer surface protein C): B. afzellii (pKo)
· p21 = OspC (outer surface protein C): B. garinii (20047)
· p41/I = (inner part of flagellin): B. bavariensis (pBi)
· VIsE: fusion proteins of different Borrelia genospecies

Click here for MSDS
Click here for PRODUCT LEAFLET 

Back to top